ISOLERE BIO INC

Durham, NC · Biotech · Acquired

ViraTag™, a liquid-liquid phase separation platform for purifying AAV gene therapy vectors from cell culture media

isolerebio.com →
Grants
$7.3M
14 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
1 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Chromatography-Free Antibody Purification by Affinity-Phase Separation$223,951
Federal grantDepartment of Health and Human Services · Phase I · Chromatography-Free Antibody Purification by Affinity-Phase Separation$223,951
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Non-Chromatographic Method for the Purification of Monoclonal Antibodies$269,999
Federal grantDepartment of Health and Human Services · Phase II · Chromatography-Free Antibody Purification by Affinity-Phase Separation$778,207
Federal grantDepartment of Health and Human Services · Phase II · Chromatography-Free Antibody Purification by Affinity-Phase Separation$1,500,000
Federal grantDepartment of Health and Human Services · Phase II · Chromatography-Free Antibody Purification by Affinity-Phase Separation$721,793
Federal grantDepartment of Health and Human Services · Phase II · ViraTag: A Scalable Purification Technology for Adeno-Associated Virus Gene Therapy Vectors$224,890
Federal grantDepartment of Health and Human Services · Phase I · Combined RNA Production and Purification Reagents Using Liquid-Liquid Phase Separating Biopolymers$255,516
Federal grantDepartment of Health and Human Services · Phase I · Combined RNA Production and Purification Reagents Using Liquid-Liquid Phase Separating Biopolymers$255,516
Federal grantDepartment of Health and Human Services · Phase I · LentiTag: A novel approach to the efficient manufacturing of active lentiviral vectors$255,556
Federal grantDepartment of Health and Human Services · Phase I · LentiTag: A novel approach to the efficient manufacturing of active lentiviral vectors$255,556
Federal grantNational Science Foundation · Phase II · SBIR Phase II:Non-Chromatographic Method for the Purification of Viral Vectors$902,504
Federal grantDepartment of Health and Human Services · Phase II · ViraTag: A Scalable Purification Technology for Adeno-Associated Virus Gene Therapy Vectors$735,839
Federal grantDepartment of Health and Human Services · Phase II · ViraTag: A Scalable Purification Technology for Adeno-Associated Virus Gene Therapy Vectors$735,839
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2142CELLECHO INC——
2143Calico——
2144Scinai Immunotherapeutics Ltd.—$3.0M
2145ISOLERE BIO INC——
2146Origin Life Sciences, Inc.—$2.9M
2147KALION, INC.—$6.7M
2148VIRONGY, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 5
  • Compositions Comprising Aav-binding Polypeptides And Methods Of Using The Sameapplication
  • Protein-based Purification Matrices And Methods Of Using The Samegranted
  • Protein-based Purification Matrices And Methods Of Using The Sameapplication
  • Protein-based Purification Matrices And Methods Of Using The Sameapplication
  • Genetically Encoded Polypeptide For Affinity Capture And Purification Of Biologicsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.